Researchers at Purdue University have identified compounds with potent antibacterial activities.

Vancomycin-resistant enterococcus (VRE) is a leading cause of hospital-acquired infections in the U.S.

Bacteriocins, antimicrobial peptides produced by certain bacteria, exhibit significant potency against other bacteria, including antibiotic-resistant strains.

The loss of a single gene causes spinal muscular atrophy, a devastating disease that is among the leading genetic causes of infant death.

A research group led by Dr. Todd Grazia, Dr. Martin Zamora and Mr. Robert Plenter developed a method for preventing acute transplant rejection and increasing graft survival.

Lymphoma immunotherapy can result in durable immune and clinical responses.

Diabetes mellitus (DM) impairs the healing of fractures and there is a need for improved therapeutics to stimulate bone regeneration in diabetic patients.

Natural killer cells suppress the magnitude and quality of vaccine responses.

A class of novel small molecule compounds to attenuate cell and tissue damage due to diabetes was developed at UMKC, and preclinical data shows highly significant reversal of hyperglycemia mediated cell and tissue damage in late-stage diabetes.

A new family of fast-acting and quickly reversible boron based neuromuscular blockers can enable tracheal intubation and maintain muscle paralysis during surgery.

New drugs help treat multiple myeloma and other types of cancer by targeting a protein called geranylgeranyl diphosphate synthase, also known as GGDPS.

Shannon Pharmaceuticals, Inc. is an Omaha, Nebraska, start-up company focusing on the development of therapeutic interventions for nephrotic diseases.

Dr. Huntington Potter and Dr. Timothy Boyd, have shown that subcutaneous Leukine administration significantly reduced brain amyloidosis and completely reversed cognitive impairment while increasing hippocampal synaptic area and microglial density in a mouse model of Alzheimer’s Disease (AD).

Structural modification of a non-selective aminocyclohexanol-based heat shock protein 90 KDa (Hsp90) inhibitor led to a highly selective inhibitor of glucose regulated protein 94 kDa (Grp94).

Novel KOR antagonists can be developed as a therapeutic treatment for mental conditions such as depression and anxiety related disorders.

Researchers at Purdue University have developed a new liposomal formulation of combinational antibiotics for the treatment of respiratory infections.

Immunotherapy using checkpoint inhibitors, especially PD-1/PD-L1 inhibitors, has now evolved into the most promising therapy for cancer patients.

SalvePed is developing ND-336 for the treatment of diabetic foot ulcers.

Certus Therapeutics provide a novel nanoparticle drug delivery platform (Lypos) for cancer chemotherapies with enhanced tumor-targeting properties.

Cincinnati Children’s has developed novel small molecule inhibitors that target both IRAK1/4 and mutant FLT3, thereby eradicating leukemic cells.

An extracted form of purified crocetinic acid from saffron has demonstrated significant anti-tumor activity against pancreatic cancer cells in a mouse model with low toxicity.

This novel analog targets the COX/LOX pathways for relief of pain and inflammation, without the negative side-effects of typical COX-2 inhibitors (GI, renal, cardiovascular), especially with chronic administration.

The development of Ewing Sarcoma therapeutics revolves around the natural product anticancer agent mithramycin (MTM), which was recently shown to be a potent inhibitor of Ewing sarcoma cells in culture and mice, by disrupting the activity of the aberrant transcription factor EWS-FLI1.

Novel cardioprotective vasodilator peptides with enhanced affinity for AM and CGRP receptors have been developed.

A University of Colorado research group led by Dr. Paco Herson has generated peptides and peptide constructs that are fused to a cell-permeable sequence, and specifically inhibits TRPM2 channel activity.

CartilaGen’s technology is an intra-articular injection of drug suspended in a hydrogel vehicle.

While there are many successes in protease inhibitor drug development including antivirals, anti-cancer and others in preclinical stages, most developments have failed due to weak PK and oral bioavailability of the inhibitors.

Novel inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) can treat cancer, and also has potential in other NAMPT-related conditions like Alzheimer’s disease, diabetes and arthritis.

Prostate-specific membrane antigen (PSMA) is the most validated marker for prostate cancer.

Cincinnati Children’s investigators have generated several potent non-toxic small molecules that directly bind to a specific Rac activator and inhibit Rac signaling in vitro and in vivo.

This novel small molecule inhibits ARID3a and results in inhibition of IFNa levels

Mayo Clinic researchers have developed a small molecule inhibitor of Cyclophilin B (CypB) and PIKfyve kinase for use in treating a variety of cancers, including lymphoblastic leukemia and lymphoma.

Mayo Clinic researchers have developed a fibrin-based hydrogel that can support an induced pluripotent stem cell (iPSC) derived retinal pigment epithelial (RPE) monolayer during differentiation but can be degraded in a matter of hours “on demand”.

Though incurable, multiple myeloma is treatable and the current treatments include steroids, chemotherapy, covalent proteasome inhibitors, immunomodulatory drugs, and stem cells transplants. UK researchers have discovered a novel pyrazole scaffold compound that targets the active site of proteasomes.

Mayo Clinic researchers have developed a novel technology to define new repertoires of tumor antigen(s) which work alone or in combination to generate anti-tumor immune responses.